The Skinny on Skinny Labels: The Active Inducement Problem That Patent Practitioners Should Know

On January 16, 2026, the United States Supreme Court agreed to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), a case that will directly shape the future of generic drug competition and the scope of induced patent infringement liability. For pharmaceutical companies, patent practitioners, and healthcare stakeholders alike, this case presents one of the most consequential intersections of patent law and drug regulation in recent memory.... By: Haug Partners LLP